BrainsWay to Report Fourth Quarter and Full Year 2025 Financial Results on March 11, 2026

BrainsWay Ltd. (NASDAQ & TASE: BWAY), a pioneering company in the field of noninvasive neurostimulation technologies, has announced that it will report its fourth quarter and full year 2025 financial results on March 11, 2026. This release will occur before the U.S. financial markets open, providing investors and analysts with a timely update on the company's performance. The announcement was made on February 25, 2026, from BrainsWay's headquarters in Burlington, Massachusetts, and Jerusalem.

On the same day, the company will conduct a conference call and webcast at 8:30 AM Eastern Time to discuss the financial results as well as operational highlights. Interested parties can participate by dialing in or accessing a live webcast through the company's investor relations website. The conference call will also be available for replay for 30 days following the event, ensuring that stakeholders can stay informed.

Founded in 2003, BrainsWay has emerged as a leader in the neurostimulation arena, specializing in its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS™) technology. This innovative platform is recognized for its efficacy in treating mental health disorders, with FDA approvals for three major indications: major depressive disorder, obsessive-compulsive disorder, and smoking addiction. The company's commitment to advancing neuroscience is backed by robust clinical trials that continue to explore additional applications of Deep TMS for various psychiatric, neurological, and addiction disorders.

With operations spanning the United States and Israel, BrainsWay is focused on enhancing global awareness and accessibility to its transformative treatments. For further information and updates leading up to the financial results announcement, interested parties are encouraged to visit BrainsWay's official website.

As BrainsWay Ltd. (NASDAQ: BWAY) prepares to report its fourth quarter and full year 2025 financial results on March 11, 2026, investors should remain vigilant, considering both potential opportunities and risks associated with the stock. The company's innovative approach to noninvasive neurostimulation, particularly its Deep Transcranial Magnetic Stimulation (Deep TMS™) technology, positions it favorably in the burgeoning mental health market. With FDA-clearances across three indications—including major depressive disorder and obsessive-compulsive disorder—BrainsWay is establishing a strong foothold where traditional treatment options are often inadequate.

Investors would be wise to analyze the anticipated earnings report closely, as insights into revenue growth, operational efficiency, and ongoing clinical trials could significantly impact share performance. The upcoming conference call and webcast will provide a platform for management to discuss key operational highlights, paving the way for clearer expectations moving forward. Listening to these discussions and management's commentary will be essential in gauging future revenue streams and addressing investor concerns.

Market sentiment surrounding mental health solutions has been shifting positively, and as BrainsWay continues to expand clinical trials into additional psychiatric and neurological disorders, this could create greater upside potential. However, it will be crucial to track developments in competitive landscapes and regulatory environments, especially as rival entities may seek to innovate in similar therapeutic areas.

Investors should consider positioning themselves ahead of the earnings release, evaluating whether expectations are properly baked into the stock price. On the flip side, caution is warranted; any unanticipated regulatory hurdles or disappointing clinical trial results could lead to volatility. In summary, maintaining an informed and balanced perspective will be key for investors looking to navigate BrainsWay's performance in the upcoming financial updates.